Dr. KSS will use the discussion section below to comment and update on what he learns from the 2018 Investor Conference/MicroCap Showcase hosted by Noble Capital Markets, taking place January 29 and 30. He expects to begin coverage by midday on January 29.
No, Balthasar is not a biotech company. Think fast! Aragorn, Legolas and Gimli. Athos, Porthos and Aramis. Jaclyn, Farrah and Kate. Kirk, Spock and Bones. Barry, Robin and Maurice. Shadrach, Meshach and Abednego. History and culture bestow trios upon us because threesomes keep us rapt. The Three Magi, liking the Gummune as they do, have […]
Dr. KSS will be reporting from the Biotech Showcase in San Francisco in the comments below. Enjoy!
[Ed. Note: Dr. KSS is our biotech and medical maven, who writes for the Irregulars. He has agreed to our trading restrictions, chooses is own topics, and his words and opinions are his own. You can find all of his previous articles and most recent comments on his Stock Gumshoe page.] Although the drive to […]
Arch Therapeutics ($ARTH) has withdrawn its 501(k) device-approval marketing application with the FDA. I spoke with CEO Terrence Norchi, MD, MBA, by phone this morning for clarification and to ask a few questions. Norchi explained that he regards Arch’s relationship with the FDA as “good and friendly” and wants to be cautious not to jeopardize […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He’s agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see his past articles and most recent comments here.] The death of Mr. Chiang, who was always kind, has never set well […]
[Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He adheres to our trading restrictions, choses his own topics, and his words and opinions are his own. His past articles and most recent comments can be found at his Stock Gumshoe page.] Dr. Norchi called me at home this morning to provide […]
The conference is exclusively one on one meetings that each attendee has with each presenting company, so lots of face time and note taking. I will disperse my notes from this conference in the comment thread below.
Dr. KSS will be live blogging in the comments section below.
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for our Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Visit his Stock Gumshoe page for more.] Bacteria are prokaryotes. Animal cells, fungi and plants are eukaryotes. Prokaryotes tend to be acellular and […]
Dr. KSS will be live blogging from the conference in the comments below.
Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]
This will be used for “live blogging” in the discussion section below.
This will be used for “live blogging” in the discussion section below.
Glenn Newberry in an earlier post today was asking whether Benlysta from GlaxoSmithKline (GSK), being trialled for lupus nephritis, poses any threat to Aurinia (AUPH). Benlysta is a monoclonal antibody that binds to and inhibits BAFF (B-cell activating factor). A company called Anthera (ANTH) is trialling blisibimod, an oral agent that does the same thing. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his past articles and most recent comments on his Stock Gumshoe page.] On Monday, April 24, 2017, Dr. […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his words and opinions are his own. You can see all of his past articles and most recent comments at his Stock Gumshoe page.] In June 2016, we advanced ScyNexis […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]